Revive Therapeutics Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Frank
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- The Canadian Venture Building Toronto ON Canada M5C 1P1
- IPO Date
- Dec 2, 2015
- Website
- revivethera.com
- Similar Companies
- Business
- Revive Therapeutics Ltd. (CSE: RVV, OTCQB: RVVTF) develops therapeutics for infectious diseases, medical countermeasures, rare disorders, and mental health conditions. The company offers Bucillamine, a disease-modifying anti-rheumatic drug under exploration for treating COVID-19, influenza, long COVID, nerve agent exposure, public health emergencies, and rare inflammatory disorders; Psilocybin-based therapeutics in Phase 1 for methamphetamine use disorder, depression, anxiety, bipolar disorder, and other mental health indications; and molecular hydrogen compositions targeting neurological disorders including ALS, dementia, Parkinson's disease, traumatic brain injury, and mental health disorders such as depression and PTSD. Founded in 2012 and headquartered in Toronto, Canada, Revive Therapeutics operates primarily in North America and pursues FDA incentives like Orphan Drug, Fast Track, and Breakthrough Therapy designations. Recent developments include the April 2025 acquisition of a molecular hydrogen program from DiagnaMed Holdings Corp., expanding its pipeline into brain health therapies with an FDA orphan drug designation for ALS; multiple private placement financings in 2025 raising approximately $650,000 through unit issuances for working capital and operations; ongoing updates to a Defence Research and Development Canada study evaluating Bucillamine for nerve agent-induced brain injury, with completion nearing; and a strategic refocus on Bucillamine for infectious diseases and countermeasures.
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics Announces Extension of Proposed Private Placement
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics Announces Proposed Shares for Debt Transaction
Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics Announces Results of Annual Shareholder Meeting
Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke